Light Your Way With Bethyl's Tools for Immuno-Oncology Research
When it comes to your tumor immune response research, blind spots are unacceptable. Independent testing has demonstrated that 75% of antibodies in today’s market are non-specific or simply do not work at all.* But at Bethyl, they manufacture and validate every antibody they make on site to ensure target specificity and sensitivity. All to guarantee their antibodies will function as designed in your assay 100% of the time. More than 10,000 independent citations over the past 15 years have proven that, at Bethyl, they put a lot in every drop.
Bethyl’s rabbit anti-PD-L1 recombinant monoclonal antibody [BLR020E] (A700-020) is 8X more sensitive than the leading competitor. Antibodies were tested in accordance to the manufacturer’s product datasheet, which seeks to optimize antibody performance.